Peisheng Hu

This inventor holds 12 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of Southern California, Cancer Therapeutics Laboratories, Inc.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peisheng Hu. Retrieved from https://idiyas.com/inventor/peisheng-hu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 14)

% Patents Active = 58.3

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 134(Granted Patents)

Location History:

Covina, CA (US) (2008 - 2021)
Los Angeles, CA (US) (2022 - 2023)

Company Filing History:

10 out of 1,694

University of Southern California

patents

2 out of 2

Cancer Therapeutics Laboratories, Inc.

patents

Years Active: 2008-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258421 - Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy (2025-03-25),

2. 11667715 - Lym-1 and Lym-2 antibody compositions and improved car constructs (2023-06-06),

3. 11384157 - Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy (2022-07-12),

4. 11136401 - Car t-cell therapy directed to LHR for the treatment of solid tumors (2021-10-05),

5. 10961317 - CD20 scFv-ELPs methods and therapeutics (2021-03-30),

6. 10196435 - OX40L fusion protein for the immunotherapy of tumors of veterinary animals (2019-02-05),

7. 8795672 - Compositions and methods for cancer immunotherapy (2014-08-05),

8. 8545838 - Compositions and methods for cancer immunotherapy (2013-10-01),

9. 8124066 - Methods of using interleukin-2 mutants with reduced toxicity (2012-02-28),

10. 7803361 - Therapeutic use of interleukin-2 mutants (2010-09-28),

11. 7514073 - Therapeutic use of interleukin-2 mutants (2009-04-07),

12. 7371371 - Interleukin-2 mutants with reduced toxicity (2008-05-13),

Title: Peisheng Hu: Innovator in Cancer Therapy

Introduction

Peisheng Hu is a prominent inventor based in Covina, California, known for his significant contributions to cancer therapy. With a total of 12 patents to his name, he has made remarkable advancements in the field of immunology and targeted therapies.

Latest Patents

Among his latest patents, Hu has developed humanized anti-nuclear antibodies aimed at targeting necrosis in cancer therapy. These humanized monoclonal antibodies exhibit enhanced binding affinity and tumor uptake, with site-directed mutants of H-CDR3 showing up to an 8-fold improvement in affinity compared to their non-humanized counterparts. Additionally, he has worked on Lym-1 and Lym-2 antibody compositions and improved chimeric antigen receptor (CAR) constructs. These innovations include antibodies and CAR cells that comprise the antigen binding domains of these antibodies, along with methods for producing and utilizing them in cancer detection and treatment.

Career Highlights

Peisheng Hu has held positions at notable institutions such as the University of Southern California and Cancer Therapeutics Laboratories, Inc. His work has been pivotal in advancing therapeutic strategies for cancer treatment.

Collaborations

Throughout his career, Hu has collaborated with esteemed colleagues, including Alan L Epstein and Jiali Li, contributing to the development of innovative cancer therapies.

Conclusion

Peisheng Hu's work in the field of cancer therapy exemplifies the impact of innovative thinking and research in medicine. His patents and collaborations continue to pave the way for advancements in targeted cancer treatments.

Profile summary based on public USPTO records.